Overview

Artificial Axon Labs is developing a transformational drug discovery platform to discover medicines for neurodegenerative diseases. Our technology, developed by the company founders at MIT, combines novel biocompatible materials, state-of-the-art 3D printing of axon mimics (Artificial Axons), and patient-derived human cells to generate first-in-class remyelinating drugs for Multiple Sclerosis.

Leadership
  • Anna Jagielska, PhD

    President, CEO, CSO, & Co-Founder

  • Kavin Kowsari

    Vice President, CTO, & Co-Founder

See all alumni